TP53 and neoplasm: Riva et al. described their study that massively parallel sequencing (MPS) was performed on patients with nonmetastatic triple-negative breast cancer (TNBC) and droplet digital PCR (ddPCR) was used to monitor TP53 mutations expressed in tumor tissues (Riva et al., 2017).